Sunny Al-Shamma, Ph.D.
President & CEO
Sunny Al-Shamma has more than 20 years of drug discovery experience in the biotech industry, most recently at Arena Pharmaceuticals where he was VP of Discovery Biology. In this role he oversaw the activity of multidisciplinary teams of biologists focused on the discovery of small molecule GPCR ligands for the treatment of Metabolic, CNS, Inflammatory and Cardiovascular diseases. This discovery group had a hand in advancing more than a dozen candidates into preclinical and clinical development in these disease areas. Prior to Arena, Sunny was Director of Biology at Maxia Pharmaceuticals where he focused on the discovery and development of small molecule nuclear receptor ligands and kinase/phosphatase modulators for the treatment of metabolic diseases and cancer. Sunny was a post-doctoral fellow at the University of California, Los Angeles, and has a Ph.D. in Neuroscience and Behavior from the University of Massachusetts, Amherst.